NCT04345406View on ClinicalTrials.gov

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2029

Conditions
COVID
Interventions
DRUG

ACEIs

Captopril or enalapril

DRUG

Conventional treatment

alexoquine

Trial Locations (1)

35111

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT04345406 - Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19 | Biotech Hunter | Biotech Hunter